化学
生化工程
质量(理念)
药物发现
药物开发
设计质量
风险分析(工程)
小分子
纳米技术
药品
药理学
工程类
业务
物理化学
哲学
认识论
粒径
材料科学
医学
生物化学
作者
Maria A. Khalikova,Jakub Jireš,Ondřej Horáček,Michal Douša,Radim Kučera,Lucie Nováková
摘要
Abstract The role of mass spectrometry (MS) has become more important in most application domains in recent years. Pharmaceutical analysis is specific due to its stringent regulation procedures, the need for good laboratory/manufacturing practices, and a large number of routine quality control analyses to be carried out. The role of MS is, therefore, very different throughout the whole drug development cycle. While it dominates within the drug discovery and development phase, in routine quality control, the role of MS is minor and indispensable only for selected applications. Moreover, its role is very different in the case of analysis of small molecule pharmaceuticals and biopharmaceuticals. Our review explains the role of current MS in the analysis of both small‐molecule chemical drugs and biopharmaceuticals. Important features of MS‐based technologies being implemented, method requirements, and related challenges are discussed. The differences in analytical procedures for small molecule pharmaceuticals and biopharmaceuticals are pointed out. While a single method or a small set of methods is usually sufficient for quality control in the case of small molecule pharmaceuticals and MS is often not indispensable, a large panel of methods including extensive use of MS must be used for quality control of biopharmaceuticals. Finally, expected development and future trends are outlined.
科研通智能强力驱动
Strongly Powered by AbleSci AI